The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 31, 2020
Filed:
May. 08, 2017
Applicant:
City of Hope, Duarte, CA (US);
Inventors:
Don Diamond, Glendora, CA (US);
Zhongde Wang, Mount Pleasant, SC (US);
Assignee:
CITY OF HOPE, Duarte, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/285 (2006.01); A61K 39/12 (2006.01); A61K 39/245 (2006.01); C07K 14/005 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/285 (2013.01); A61K 39/12 (2013.01); A61K 39/245 (2013.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); A61K 2039/5256 (2013.01); C07K 2319/40 (2013.01); C12N 2710/16134 (2013.01); C12N 2710/16151 (2013.01); C12N 2710/24143 (2013.01); C12N 2830/60 (2013.01);
Abstract
A method of preventing, controlling or treating CMV infections with a vaccine comprising an immunologically effective amount of a fusion cytomegalovirus (CMV) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of Immediate-Early Gene-1 or Immediate-Early Gene-2 (IEfusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine.